Litak: Uses, Dosage & Side Effects

What Is Litak and What Is It Used For?

Litak contains the active substance cladribine (2-chlorodeoxyadenosine, 2-CdA), a synthetic purine nucleoside analog that belongs to the class of antimetabolite chemotherapy agents. Cladribine was first synthesized in the 1970s and its remarkable efficacy against hairy cell leukemia was established through landmark clinical trials in the 1980s and 1990s. The development of cladribine represented a major breakthrough in the treatment of HCL, transforming a difficult-to-treat chronic leukemia into one of the most treatable blood cancers.

Hairy cell leukemia is a rare, chronic B-cell lymphoproliferative disorder that accounts for approximately 2% of all leukemias. The disease derives its name from the characteristic fine, hair-like projections visible on the surface of the malignant B-lymphocytes when examined under a microscope. HCL typically presents with splenomegaly (enlarged spleen), pancytopenia (low blood cell counts), and an increased susceptibility to infections. The disease predominantly affects middle-aged and older men, with a male-to-female ratio of approximately 4:1. While the exact cause remains unknown, HCL is characterized by the near-universal presence of the BRAF V600E mutation in malignant cells.

The mechanism of action of cladribine is uniquely suited to treating lymphoid malignancies. As a purine nucleoside analog, cladribine enters cells and is phosphorylated by the intracellular enzyme deoxycytidine kinase (dCK) to form its active triphosphate metabolite, 2-chlorodeoxyadenosine triphosphate (2-CdATP). Lymphocytes, including the malignant B-cells of hairy cell leukemia, have particularly high levels of dCK relative to the opposing enzyme 5′-nucleotidase, which would otherwise dephosphorylate and inactivate the drug. This favorable enzyme ratio in lymphocytes means that cladribine is selectively activated and concentrated in the very cells it is intended to destroy.

Once the active triphosphate form accumulates within the cell, it exerts its cytotoxic effects through multiple mechanisms. In actively dividing cells, 2-CdATP is incorporated into newly synthesized DNA, causing strand breaks and inhibiting DNA synthesis. In resting (non-dividing) cells – which represent the majority of hairy cell leukemia cells – the drug disrupts DNA repair processes, depletes cellular stores of nicotinamide adenine dinucleotide (NAD+) and adenosine triphosphate (ATP), and activates caspases that trigger apoptosis (programmed cell death). This ability to kill both dividing and quiescent lymphocytes distinguishes cladribine from many other chemotherapy agents and is fundamental to its exceptional efficacy in HCL.

Litak is specifically formulated as a ready-to-use solution for subcutaneous injection at a concentration of 2 mg/ml. This formulation offers several practical advantages over the intravenous cladribine preparations that were historically used. Subcutaneous administration allows treatment to be given on an outpatient basis, avoiding the need for continuous intravenous infusion pumps or prolonged hospital stays. Pharmacokinetic studies have demonstrated that subcutaneous cladribine achieves bioavailability approaching 100%, with comparable clinical efficacy to the intravenous route. The European Medicines Agency (EMA) granted marketing authorization for Litak based on evidence demonstrating its clinical effectiveness and the convenience of the subcutaneous route.

What Should You Know Before Taking Litak?

Contraindications

There are several absolute contraindications that must be carefully assessed before initiating treatment with Litak. Your doctor will evaluate these conditions thoroughly during the pre-treatment assessment.

• Hypersensitivity: Do not use Litak if you are allergic to cladribine or any of the excipients in the formulation (sodium chloride, water for injections, and hydrochloric acid/sodium hydroxide for pH adjustment).
• Pregnancy and breastfeeding: Litak is absolutely contraindicated during pregnancy. Cladribine has demonstrated teratogenic effects in animal studies, and its mechanism of action (DNA damage and inhibition of DNA repair) poses a serious risk of birth defects and fetal harm. Breastfeeding must be discontinued during and after treatment.
• Severe renal impairment: Patients with creatinine clearance below 30 ml/min should not receive Litak, as impaired renal function can lead to accumulation of the drug and its metabolites, increasing the risk of severe toxicity.
• Severe hepatic impairment: Litak should not be used in patients with severe liver dysfunction, as this may alter drug metabolism and increase toxicity risk.
• Active, uncontrolled infections: Treatment should not be initiated in patients with active, serious infections, as cladribine causes further immunosuppression that could worsen the infection and lead to life-threatening complications.

Warnings and Precautions

Before and during treatment with Litak, the following precautions and warnings apply:

• Myelosuppression: Complete blood counts must be monitored regularly before, during, and after treatment. The nadir (lowest blood counts) typically occurs 1–2 weeks after beginning treatment for neutrophils and platelets. Patients may require blood transfusions and growth factor support. Febrile neutropenia (fever with low white blood cell count) requires urgent medical evaluation and treatment with broad-spectrum antibiotics.
• Infections: The profound immunosuppression caused by cladribine increases susceptibility to bacterial, viral, and fungal infections. Prophylactic antivirals (e.g., aciclovir) and co-trimoxazole (for Pneumocystis prevention) may be recommended. Any fever during or after treatment must be treated as a medical emergency until proven otherwise.
• Tumor lysis syndrome: Rapid destruction of large numbers of malignant cells may lead to tumor lysis syndrome, a potentially life-threatening metabolic emergency. Adequate hydration and monitoring of renal function, electrolytes, and uric acid levels are essential, particularly during the first treatment cycle.
• Neurotoxicity: At standard doses used for hairy cell leukemia, significant neurotoxicity is uncommon. However, at higher doses used in some treatment protocols, peripheral neuropathy, headache, and rarely, progressive demyelinating encephalopathy have been reported. Report any new neurological symptoms promptly.
• Secondary malignancies: As with other DNA-damaging agents, there is a theoretical risk of secondary cancers following cladribine treatment. Long-term follow-up studies have shown a small but measurable increase in the incidence of secondary malignancies, though the absolute risk remains low.
• Autoimmune hemolytic anemia: Cases of autoimmune hemolytic anemia have been reported during and after cladribine therapy. Patients should be monitored for unexplained drops in hemoglobin or signs of hemolysis.
• Renal impairment: Patients with mild to moderate renal impairment may require dose adjustments and closer monitoring, as cladribine is partly eliminated through the kidneys.
• Blood product irradiation: Patients receiving cladribine who require blood transfusions should receive irradiated blood products to prevent transfusion-associated graft-versus-host disease, given the profound immunosuppression.

Regular monitoring of blood counts is essential during and for at least 4–8 weeks after treatment. Patients should be educated about the signs and symptoms of infection and advised to seek medical attention promptly if they develop fever, chills, cough, sore throat, or any other signs of infection, even months after completing treatment.

Pregnancy and Breastfeeding

Litak is contraindicated during pregnancy. Animal studies have demonstrated that cladribine is teratogenic (causes birth defects) and embryotoxic (harmful to the developing embryo). The drug’s mechanism of action – damaging DNA and inhibiting DNA repair – means it poses a fundamental risk to any rapidly developing tissue, including a developing fetus. There are no adequate and well-controlled studies in pregnant women, and the potential risks clearly outweigh any possible benefits.

Women of childbearing potential must use effective contraception during treatment and for at least 6 months after the last dose of Litak. Men must also use effective contraception for at least 6 months after treatment, as cladribine may damage sperm DNA. A pregnancy test should be performed before starting treatment. If pregnancy occurs during treatment, the patient should be informed about the potential risks to the fetus and counseled by a specialist in reproductive toxicology.

It is not known whether cladribine or its metabolites are excreted in human breast milk. Given the potential for serious adverse effects in the nursing infant, breastfeeding must be discontinued before starting treatment and should not be resumed during treatment or for a period after the last dose as determined by the prescribing physician.

How Does Litak Interact with Other Drugs?

Drug interactions with cladribine are an important consideration for safe treatment. Because cladribine causes profound immunosuppression and myelosuppression, combining it with other agents that have similar effects can significantly increase the risk of serious, potentially life-threatening complications. Your hematologist will carefully review all your current medications before initiating Litak therapy.

Cladribine is primarily eliminated by the kidneys, and drugs that affect renal function may alter its clearance. Additionally, because cladribine requires intracellular phosphorylation by deoxycytidine kinase (dCK) for activation, drugs that compete for this enzyme may theoretically reduce its efficacy, although this interaction has limited clinical significance at standard doses.

Major Interactions

Additional Interactions and Considerations

Always inform your healthcare team about all medications you are taking, including prescription drugs, over-the-counter medicines, vitamins, herbal supplements, and any complementary or alternative therapies. Some herbal products (such as echinacea or St. John’s wort) may interact with cladribine by affecting immune function or drug metabolism. It is advisable to avoid starting any new medications during and immediately after cladribine treatment without first consulting your hematologist.

What Is the Correct Dosage of Litak?

The dosing of Litak is straightforward compared to many other anticancer treatments. The standard regimen consists of a single course of subcutaneous injections, making it one of the most concise and efficient treatment protocols in oncology. Despite its brevity, this single course achieves remarkably high remission rates. The dose is calculated based on body weight, ensuring appropriate drug exposure for each individual patient.

Adults

The subcutaneous injection should be administered into the abdominal wall, the thigh, or the upper arm. Injection sites should be rotated to minimize local reactions. The solution should be clear and colorless; do not use if it appears discolored or contains particulate matter. Each vial is for single use only; any unused solution should be discarded.

Most patients require only a single course of treatment. Response to therapy is typically assessed 4–6 months after completing treatment, as the full therapeutic effect takes time to manifest. Complete remission is defined by normalization of peripheral blood counts, clearance of hairy cells from the blood and bone marrow, and resolution of splenomegaly. If a complete response is not achieved after the first course, or if the patient relapses after an initial response, a second course of cladribine may be considered, typically after an interval of at least 6–12 months. However, the likelihood of achieving complete remission decreases with subsequent courses.

Children and Adolescents

Elderly Patients

Missed Dose

As Litak is administered by a healthcare professional in a structured 5-day treatment course, missed doses are uncommon. However, if a dose is missed for any reason (for example, due to an intercurrent illness or logistical issue), the treating physician should determine the best course of action. In general, the missed injection should be given as soon as possible, and the remaining doses completed to deliver the full 5-day course. The decision to extend or restart the treatment course depends on the specific circumstances and is made on a case-by-case basis by the treating hematologist.

Overdose

There is no specific antidote for cladribine overdose. Accidental overdose would be expected to produce exaggerated pharmacological effects, particularly severe and prolonged myelosuppression, profound immunosuppression, and potentially irreversible neurotoxicity at very high doses. High doses of cladribine have been associated with irreversible paraparesis and quadriparesis, as well as severe nephrotoxicity and hepatotoxicity.

In the event of an overdose, supportive care should be initiated immediately, including close monitoring of blood counts, aggressive infection prophylaxis and treatment, blood product support (including irradiated blood products), and supportive measures for any organ toxicity that develops. Dialysis is unlikely to be effective in removing cladribine from the body due to its rapid intracellular distribution and phosphorylation. Any suspected overdose should be reported immediately to the healthcare facility responsible for the patient’s care.

What Are the Side Effects of Litak?

Like all anticancer medicines, Litak can cause side effects, although not everybody gets all of them. The most clinically significant adverse effects relate to the drug’s mechanism of action: because cladribine targets rapidly dividing cells and lymphocytes, it inevitably affects normal blood cell production and immune function. Understanding these side effects and knowing when to seek medical attention is essential for safe treatment.

The frequency of side effects is classified according to international convention: very common (affects more than 1 in 10 people), common (affects 1 to 10 in 100 people), uncommon (affects 1 to 10 in 1,000 people), and rare (affects fewer than 1 in 1,000 people). The following comprehensive list is based on data from clinical trials and post-marketing surveillance.

It is important to remember that the side effects of cladribine, particularly myelosuppression and immunosuppression, are expected consequences of the drug’s mechanism of action and are generally manageable with appropriate supportive care. The clinical team will provide detailed guidance on monitoring, infection prevention, and when to seek medical attention. Most patients tolerate the treatment well, and the side effects are considered acceptable given the high response rates and the potential for durable, long-term remission.

How Should You Store Litak?

Correct storage of Litak is essential to maintain the stability and effectiveness of the medication. As a cytotoxic agent, special handling precautions also apply. In most clinical settings, the medication is stored and handled by the pharmacy or healthcare team, but patients and caregivers should be aware of the following requirements:

• Temperature: Store in a refrigerator at 2–8°C (36–46°F). Do not freeze. If the solution has been frozen, it should not be used.
• Light protection: Keep the vials in the original outer carton to protect from light. Cladribine may degrade when exposed to prolonged light.
• Shelf life: Do not use Litak after the expiry date printed on the vial and carton. The expiry date refers to the last day of that month.
• Single use: Each vial is for single use only. Any unused solution remaining in the vial after drawing up the required dose must be disposed of according to local requirements for cytotoxic waste.
• Visual inspection: Before use, the solution should be visually inspected. It should be clear and colorless. Do not use if the solution is cloudy, discolored, or contains visible particles.
• Keep out of reach of children: As with all medicines, store Litak out of the sight and reach of children.

Healthcare professionals handling Litak should follow institutional guidelines for the safe handling of cytotoxic drugs. This includes wearing appropriate personal protective equipment (gloves, gowns) during preparation and administration. In the event of accidental skin contact with the solution, the affected area should be washed immediately and thoroughly with soap and water. Accidental exposure to the eyes should be treated by rinsing with copious amounts of water, and medical attention should be sought. All contaminated materials and waste should be disposed of according to local regulations for cytotoxic waste.

What Does Litak Contain?

Understanding the composition of Litak is important for identifying potential allergens and ensuring appropriate storage and handling. The formulation is designed to be a ready-to-use, preservative-free solution suitable for subcutaneous injection.

Active Ingredient

The active substance is cladribine (also known as 2-chloro-2′-deoxyadenosine or 2-CdA). Each milliliter of solution contains 2 mg of cladribine. Each 5 ml vial therefore contains a total of 10 mg of cladribine. Cladribine is a synthetic purine nucleoside analog with the molecular formula C₁₀H₁₂ClN₅O₃ and a molecular weight of 285.69 g/mol. It is a white to off-white crystalline powder that is slightly soluble in water.

Excipients (Inactive Ingredients)

• Sodium chloride: 9 mg/ml (used as an isotonic agent to make the solution compatible with body fluids and reduce pain at the injection site)
• Water for injections: Serves as the solvent
• Hydrochloric acid and/or sodium hydroxide: Used for pH adjustment to ensure the solution is at an appropriate pH for subcutaneous injection (approximately pH 5.5–8.0)

The formulation does not contain any preservatives, antimicrobial agents, or buffers other than those listed above. The absence of preservatives is the reason each vial is intended for single use only. The solution is isotonic and has a pH that minimizes irritation at the injection site, although mild injection site reactions may still occur.